Skip to content

Use of turmeric extract and blood clot for the treatment of bone loss due to gum disease

â??CLINICAL APPLICATION OF NOVEL HERBAL FORMULATION -1% CURCUMIN GEL AND IN CONJUNCTION WITH PLATELET-RICH FIBRIN IN THE TREATMENT OF HUMAN INTRABONY DEFECTS: A RANDOMIZED CONTROLLED CLINICAL TRIALâ??

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/05/013893
Enrollment
60
Registered
2018-05-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Presence of intrabony defect with a clinical probing pocket depth of â?¥ 6mm,with radiographic evidence,

Interventions

None listed

Sponsors

self
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients willing to undergo regenerative treatment for intrabony defects. 2.Presence of intrabony defect with a clinical probing pocket depth of >= 6mm, with radiographic evidence. 3.Systemically healthy patients. 4.Patients who have not been on any medications within the last 6 months which may alter the periodontal status.

Exclusion criteria

Exclusion criteria: 1.Patients unwilling to participate in the study. 2.Smokers and alcoholic patients. 3.Pregnant and lactating mothers. 4.Patients who have undergone periodontal treatment within the last 1 year. 5.Patients with plaque index >1 and who are unwilling to follow oral hygiene practices after phase I therapy.

Design outcomes

Primary

MeasureTime frame
reduction in probing pocket depth gain in clinical attachment levelsTimepoint: 9 months

Secondary

MeasureTime frame
reduction in probing pocket depth gain in clinical attachment levelsTimepoint: 9 months

Countries

India

Contacts

Public ContactDr Aiswarya Dileep

Rajiv Gandhi University of Health Sciences,Bangalore

kripalkrishna@yahoo.com9632597504

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026